Vladimir Putin has directed Russian scientists to accelerate work on what officials describe as the world’s first anti-ageing vaccine, placing longevity research at the centre of the country’s long-term health and biotechnology agenda.
The initiative is part of a broader national strategy by Russia to expand research into life extension, healthy ageing and advanced medical innovation. According to Russian officials, the project seeks to slow the biological processes associated with ageing and potentially improve both lifespan and quality of life.
At the heart of the programme is an experimental gene-therapy-based treatment designed to target the RAGE receptor, a cellular mechanism believed by researchers to play a major role in biological ageing. Scientists say activation of this receptor may contribute to age-related damage and deterioration in cells. By blocking it, researchers hope to slow the ageing process and preserve healthy cellular function for a longer period.
The anti-ageing research forms part of Russia’s New Technologies for Health Preservation national programme, launched in 2025. The large-scale initiative reportedly carries a budget of more than 2 trillion rubles, estimated at over $26 billion, making it one of the country’s most ambitious investments in biotechnology and medical research in recent years.
Speaking at a healthy longevity conference in Saransk, Russian Deputy Science Minister Denis Sekirinsky said the objective is to develop a specialised gene-therapy drug capable of blocking the receptor linked to cellular ageing.
“The goal is to create the world’s first gene therapy drug specifically designed to block the receptor,” Sekirinsky reportedly said.
Russian authorities say the programme is also being driven by wider demographic concerns. The country has faced years of declining population growth and relatively low male life expectancy. Current estimates place average life expectancy for Russian men at about 67 years, a figure officials hope to improve through advances in preventive healthcare and medical science.
The Kremlin has increasingly framed longevity research as both a healthcare priority and a strategic national objective. Officials argue that extending healthy lifespan could have long-term implications for public health, workforce productivity and population stability.
Russian Deputy Prime Minister Tatyana Golikova has indicated that if research and testing progress successfully, production of the treatment could begin between 2028 and 2030. At present, however, human clinical trials have not yet started.
The announcement has attracted significant international attention and triggered debate within scientific and public policy circles. Supporters view the project as an ambitious attempt to push the boundaries of medical innovation. Critics, however, have cautioned that describing the treatment as an “anti-ageing vaccine” may be misleading.
Unlike conventional vaccines, which are designed to train the immune system to prevent disease, the Russian project is understood to function more as experimental gene therapy aimed at influencing biological pathways linked to ageing.
Putin, now 73, has publicly expressed interest in longevity science and biotechnology for several years. Previous reports suggested that the Russian leader had discussed the possibility of people living to 150 years or even reaching forms of “immortality” during conversations involving Xi Jinping.
Despite the excitement surrounding the initiative, scientists continue to stress that anti-ageing research remains highly experimental across the world. At present, there is no scientifically proven treatment capable of stopping, reversing or eliminating human ageing entirely.
For now, Russia’s anti-ageing programme represents a bold scientific gamble—one that could shape future conversations around healthcare, longevity and the limits of modern biotechnology.
